Brief description of study

This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To evaluate the proportion of patients with objective response (OR) to targeted study
agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment
with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple
myeloma.

II. To evaluate time until death or disease progression. III. To identify potential
predictive biomarkers beyond the genomic alteration by which treatment is assigned or
resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and
imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes
from pre- through post-therapy imaging can predict objective response and progression free
survival and to evaluate the association between pre-treatment radiomic phenotypes and
targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE

STEP 0 (Screening): Patients undergo biopsy along with molecular characterization of the
biopsy material for specific, pre-defined mutations, amplifications, or translocations of
interest via tumor sequencing and immunohistochemistry. Consenting patients also undergo
collection of blood samples for research purposes.

STEPS 2, 4, 6 (Screening): Patients experiencing disease progression on the prior Step
treatment or who could not tolerate the assigned treatment undergo review of their previous
biopsy results to determine if another treatment is available or undergo another biopsy.
Patients may have a maximum of 2 screening biopsies and 2 treatments per biopsy.